Skip to main content

Advertisement

SpringerLink
Log in

Clinico-pathological Features of PIK3CA Mutation in HER2-Positive Breast Cancer of Indian Population

  • Original Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

PIK3CA pathway is one of the important signaling pathways in cells, which is involved in cell proliferation, cell survival, motility, and growth. Mutation in PIK3CA gene negatively effects to anti-HER2 therapy in breast cancer patients. PIK3CA gene of HER2-positive breast cancers associated with reduced sensitivity to neoadjuvant therapy. In this study, we assessed the frequency of PIK3CA mutations and influence of PIK3CA mutations on patient survival in a series of HER2-positive breast cancer patients. PIK3CA mutations were assessed by pyrosequencing and next generation sequencing in 107 HER2-positive breast cancer patients of a tertiary Cancer Centre of India from Jan 2012 to Jun 2013 with minimum follow-up of 3 years. We found PIK3CA mutations in 26 tumors (24.2%) of which 5 were in exon 9, 20 were in exon 20, and 1 was in both exon 9 and 20. In exon 9, the mutation c.1634A>G was found in 4 cases and mutation c.1636C>A was found in 2 cases. In exon 20, the mutation c.3140A>G was found in 15 cases and c.3140A>T was found in 6 cases. The outcome between PIK3CA mutated versus PIK3CA wild type was significant showing p value 0.014. Overall survival of mutation and treatment with herceptin, mutation with other chemotherapy treatment in both early breast cancer (EBC), and locally advanced breast cancer (LABC) showed significant p value 0.037 and 0.044 respectively. In conclusion, we identified 24.2% somatic mutation of PIK3CA in HER2-positive breast cancer patients. PIK3CA mutation is significantly associated with ER-positive tumors. The frequency and distribution pattern reported in this study is similar to the global report. Overall survival of PIK3CA mutation is slightly lower but in patients who received herceptin with PIK3CA mutation showed better clinical outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Panigrahi MK, Kumar D, Mehta A, Saikia KK (2017) Outcome of HER2 testing by FISH applying ASCO/CAP 2007 and 2013 guideline in IHC equivocal group of breast cancer: experience at tertiary cancer care centre. South Asian J Cancer 6:45–46. https://doi.org/10.4103/2278-330X.208841

    Article  PubMed  PubMed Central  Google Scholar 

  2. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, Higashi K, Volinia S, Downward J, Waterfield MD (1997) P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 94:4330–4335

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Zhao L, Vogt PK (2008) Class I PI3K in concogenic cellular transformation. Oncogene 27:5486–5496. https://doi.org/10.1038/onc.2008.244.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Mangone FR, Bobrovnitchaia IG, Salaorni S, Manuli E, Nagai MA (2012) PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics (Sao Paulo) 67:1285–1290. https://doi.org/10.6061/clinics/2012(11)11

    Article  PubMed Central  Google Scholar 

  5. Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V, Marchio C, Lopez-Knowles E, Ghazoui Z, Habben K, Arbogast S, Johnston S, Dowsett M (2011) Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer 18:565–577. https://doi.org/10.1530/ERC-10-0046

    Article  PubMed  CAS  Google Scholar 

  6. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC (2011) Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29:166–173. https://doi.org/10.1200/JCO.2009.27.7814

    Article  PubMed  CAS  Google Scholar 

  7. Jensen JD, Knoop A, Laenkholm AV, Grauslund M, Jensen MB, Santoni- Rugiu E, Andersson M, Ewertz M (2012) PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 23:2034–2042. https://doi.org/10.1093/annonc/mdr546

    Article  PubMed  CAS  Google Scholar 

  8. Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X (2011) PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11:248. https://doi.org/10.1186/1471-2407-11-248

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D et al (2008) PIK3CA mutation in colorectal Cancer: relationship with genetic and epigenetic alterations. Neoplasia 10(6):534–541

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Cizkova M, Dujaric ME, Lehmann-Che J, Scott V, Tembo O, Asselain B, Pierga JY, Marty M, de Cremoux P, Spyratos F, Bieche I (2013) Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer 108(9):1807–1809. https://doi.org/10.1038/bjc.2013.164

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg Å, Parsons R (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554–2559. https://doi.org/10.1158/0008-5472-CAN-04-3913

    Article  PubMed  CAS  Google Scholar 

  12. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24:1477–1480. https://doi.org/10.1038/sj.onc.1208304

    Article  PubMed  CAS  Google Scholar 

  13. Michelucci A, Di Cristofano C, Lami A, Collecchi P, Caligo A, Decarli N et al (2009) PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol 18:200–205. https://doi.org/10.1097/PDM.0b013e31818e5fa4

    Article  PubMed  CAS  Google Scholar 

  14. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt ANJ, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C (2010) PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci 107:10208–10213

    Article  PubMed  Google Scholar 

  15. Cizkova M, Susini A, Vacher S, Cizeron-Clairac G, Andrieu C, Driouch K, Fourme E, Lidereau R, Bièche I (2012) PIK3CA mutation impact on survival in breast cancer patients and in ER alpha, PR and ERBB2-based subgroups. Breast Cancer Res 14:R28. https://doi.org/10.1186/bcr3113

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Jensen JD, Knoop A, Laenkholm AV, Grauslund M, Jensen MB, Santoni-Rugiu E, Andersson M, Ewertz M (2012) PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2- positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 23:2034–2042. https://doi.org/10.1093/annonc/mdr546

    Article  PubMed  CAS  Google Scholar 

  17. Baselga J, Corte’s J, Im SA, Clark E, Ross G, Kiermaier A, Cortés J, Im SA, Clark E, Ross G, Kiermaier A, Swain SM (2014) Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 32:3753–3761. https://doi.org/10.1200/JCO.2013.54.5384

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Bioengineering and Technology, Gauhati University, Assam, 781014, India

    Kandarpa Kumar Saikia, Manoj Kumar Panigrahi & Dushyant Kumar

  2. Rajiv Gandhi Cancer Institute and research Centre, New Delhi, 110085, India

    Anurag Mehta

Authors
  1. Kandarpa Kumar Saikia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manoj Kumar Panigrahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anurag Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dushyant Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kandarpa Kumar Saikia.

Ethics declarations

Informed Consent

Informed consent was obtained from the patient.

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

This study approved by the institutional ethics committee (Institutional Review Board, Rajiv Gandhi Cancer Institute). (RGCI ID-406/PA/AMH-09).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saikia, K.K., Panigrahi, M.K., Mehta, A. et al. Clinico-pathological Features of PIK3CA Mutation in HER2-Positive Breast Cancer of Indian Population. Indian J Surg Oncol 9, 381–386 (2018). https://doi.org/10.1007/s13193-018-0749-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-018-0749-3

Keywords

Search

Navigation